Following U.S. Stocks are among the “Top Losers” in the course of recent trading session: Galena Biopharma Inc (NASDAQ:GALE), CTI BioPharma Corp (NASDAQ:CTIC), Hercules Offshore, Inc (NASDAQ:HERO), Resolute Energy Corp (NYSE:REN)
- Galena Biopharma Inc (NASDAQ:GALE), with shares dwindled -18.50% is now trading at $1.40. The Stock is active as 6.00M shares changed hands versus its average volume of 1.67M shares.
- CTI BioPharma Corp (NASDAQ:CTIC), with shares declined -14.81% is now trading at $2.22. The Stock is active as 5.46M shares changed hands versus its average volume of 3.81M shares.
- Hercules Offshore, Inc (NASDAQ:HERO) with shares dipped -15.65% is now trading at $0.370. The Stock is active as 1.80M shares changed hands versus its average volume of 4.04M shares.
- Resolute Energy Corp (NYSE:REN), with shares dropped -7.85% is now trading at $0.654, hitting new 52-week high of $0.64. The Stock is active as 265,807.00 shares changed hands versus its average volume of 1.13M shares.
Latest NEWS regarding these Stocks are depicted underneath:
Fura Emeralds Inc. (NASDAQ:GALE)
Fura Emeralds Inc. (GALE), a biopharmaceutical corporation developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, declared the pricing of an underwritten public offering of 24,358,974 units at a public offering price of $1.56 per unit, for total gross proceeds of $38.0 million. Each unit comprises of one share of ordinary stock and a warrant to purchase 0.5 of a share of ordinary stock at an exercise price of $2.08 per share. The warrants are right away exercisable and expire on the fifth anniversary of the date of issuance. The shares of ordinary stock and warrants are right away separable and will be issued separately.
The offering is predictable to close on March 18, 2015, subject to customary closing conditions. Galena has granted the underwriters a 30-day option to purchase up to an additional 3,653,846 shares of ordinary stock and/or additional warrants to purchase up to 1,826,923 shares of ordinary stock to cover over-allotments, if any.
Raymond James & Associates, Inc. is acting as the sole book-running manager for the offering. Roth Capital Partners is acting as lead manager, and Maxim Group LLC, MLV & Co. LLC, and Noble Life Science Partners are acting as co-managers.
The corporation intends to use the net proceeds from this offering to fund its operations, counting the ongoing commercialization of Abstral(R) (fentanyl) Sublingual Tablets and Zuplenz(R) (ondansetron) Oral Soluble Film, its ongoing Phase 3 PRESENT study and other clinical trials of its product candidates, and for other working capital and general corporate purposes.
Fura Emeralds Inc. (GALE), a natural resource corporation, attains and explores mineral properties in Canada and internationally. It has a 51% interest in the Iron Horse Property that comprises of 7 mining tenures covering an area of 1,915 hectares and is located in Skeena and Liard Mining Divisions, British Columbia, Canada. The corporation was formerly known as Wolf Resource Development Corp. and changed its name to Fura Emeralds Inc. in March 2015. Fura Emeralds Inc. was incorporated in 2006 and is based in Toronto, Canada.
CTI BioPharma Corp. (NASDAQ:CTIC)
CTI BioPharma Corp. (CTIC), stated financial results for the fourth quarter and full year ended December 31, 2014.
Recent Highlights:
Pacritinib:
In March 2015, stated top-line results for the primary endpoint from the PERSIST-1 Phase 3 clinical trial of pacritinib for the treatment of patients with myelofibrosis. The trial met its primary endpoint in the intent-to-treat population with statistically noteworthyactivity observed in patients irrespective of their initial platelet count, counting patients with very low platelet counts at study entry. The primary endpoint of the trial was the proportion of patients achieving a 35 percent or greater reduction in spleen volume from baseline to Week 24 as measured by magnetic resonance imaging (MRI) or computerized tomography (CT) when contrast with physician-specified best accessible therapy (BAT), not including treatment with JAK2 inhibitors.
In December 2014, declared presentation of pacritinib data at the American Society of Hematology Annual Meeting. A pre-clinical study demonstrated a unique kinome profile for pacritinib among agents in development for myelofibrosis and suggests potential therapeutic benefit across a spectrum of blood-related cancers such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and chronic lymphocytic leukemia (CLL). A separate pre-clinical study presented showed that pacritinib overrides stromal mediated resistance in FLT3-ITD positive AML cells, which is believed to be an important mechanism of resistance to other FLT3 antagonists in treating AML.
PIXUVRI:
In February 2015, The Spanish Directorate General of Pharmacy and Health Products, part of the Spanish Ministry of Health, approved the reimbursement of PIXUVRI (pixantrone) for the treatment of patients with aggressive B-cell non-Hodgkin lymphoma (NHL). PIXUVRI will be comprised of in the national list of accessible reimbursed products commencing March 1, 2015. CTI BioPharma’s partner, Servier, holds the commercialization rights to PIXUVRI and will be responsible for the launch of the drug in Spain. As a result of such reimbursement approval in Spain, CTI BioPharma received a €1.5 million milestone payment from Servier.
Corporate:
In January 2015, designated Alan K. Burnett, M.D., to serve as the planned leader for myeloid development. Dr. Burnett most recently served as Professor and Head of the Department of Haematology in the Institute of Cancer and Genetics at Cardiff University and is highly regarded internationally for his work in the treatment of AML and MDS.
CTI BioPharma Corp. (NASDAQ:CTIC) is a biopharmaceutical corporation focused on the attainment, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers.
Hercules Offshore, Inc. (NASDAQ:HERO)
In according to analyst opinion, in this week, the mean recommendation for the stock of Hercules Offshore, Inc. (HERO), is 3.1, while for the last week it was also on 3.1 i.e., “SELL”.
On Feb 27, 2015, Deutsche Bank, updated its action and downgraded the stock from “Buy” to “Sell”. Looking into the history, then Deutsche Bank was the research firm which upgraded the stock from “Hold” to “Buy”, on Nov 28, 2012.
In the current month the stock recommendation trend shows that it is recommended “Buy” for 5 Times, “Hold” for 8 Times, and Underperform for “4” Times. None of the analyst recommended this stock to be A “Strong Buy”, or “SELL”, indicating that it is the mediocre stock.
Hercules Offshore, Inc., together with its auxiliaries, provides shallow-water drilling and marine services to the oil and natural gas exploration and production industry worldwide.
Resolute Energy Corporation (NYSE:REN)
The beta value of Resolute Energy Corporation (REN) stock is 3.36, indicating that it is the most volatile stock in the market. The stock price history shows that it lastly hit its 52-week High of $8.98, on Jun 16, 2014, and its 52-week-low of $0.64 on Jan 14, 2015, and the overall change in 52-week range comprise -90.77% loss.
Looking into the share statistics we come to know that Average Volume of the stock for the last 3 Months remained 1,408,590, while for the last 10 days it was 775,038 on average. The company has outstanding shares of 74.87M. 9.16% of the shares are held by insiders, however remaining 96.10% of shares are held by institutions.
During the current trade the company attained the volume of 494,231 as compared to its all time average volume of 1,408,590. The company holds the market capitalization of 47.98M.
Resolute Energy Corporation, an independent oil and gas corporation, attains, explores for, develops, and produces oil, gas, and hydrocarbon liquids. It holds interest in the Aneth Field covering about 43,000 gross acres located in the Paradox Basin in southeast Utah; and 36,500 gross acres in the Permian Basin of Texas and southeast New Mexico. The corporation also owns leases covering about 47,400 net acres in the Powder River Basin; and about 34,700 net acres in the Big Horn Basin in Wyoming.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
